Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?

Glioblastoma (GBM), the most common primary malignant brain tumor, is associated with a dismal prognosis. Standard therapies including maximal surgical resection, radiotherapy, and temozolomide chemotherapy remain poorly efficient. Improving GBM treatment modalities is, therefore, a paramount challe...

Descripción completa

Detalles Bibliográficos
Autores principales: Echavidre, William, Picco, Vincent, Faraggi, Marc, Montemagno, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144720/
https://www.ncbi.nlm.nih.gov/pubmed/35631639
http://dx.doi.org/10.3390/pharmaceutics14051053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144720/
https://www.ncbi.nlm.nih.gov/pubmed/35631639
http://dx.doi.org/10.3390/pharmaceutics14051053

Ejemplares similares